Toxicity Clinical Trials

151 recruitingLast updated: June 17, 2026

There are 151 actively recruiting toxicity clinical trials across 37 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include Toronto, Ontario, Canada, Amsterdam, Netherlands, Detroit, Michigan, United States. Updated daily from ClinicalTrials.gov.


Toxicity Trials at a Glance

151 actively recruiting trials for toxicity are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Not Applicable with 54 trials, with the heaviest enrollment activity in Toronto, Amsterdam, and Detroit. Lead sponsors running toxicity studies include Johns Hopkins University, Odense University Hospital, and Erasmus Medical Center.

Treatments under study

About Toxicity Clinical Trials

Looking for clinical trials for Toxicity? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Toxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Toxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 151 trials

Recruiting
Not Applicable

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

Breast CancerAnthracycline Related Cardiotoxicity in Breast CancerTrastuzumab+1 more
Virginia Commonwealth University30 enrolled3 locationsNCT07426913
Recruiting
Phase 1Phase 2

The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

ToxicityRadiation Toxicity
UNC Lineberger Comprehensive Cancer Center122 enrolled1 locationNCT04700527
Recruiting
Phase 2

Rivastigmine for Antimuscarinic Delirium

Anticholinergic Toxicity
Washington University School of Medicine42 enrolled1 locationNCT06382649
Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Heart FailureCardiotoxicityMyocardial Infarction+12 more
Peerbridge Health, Inc2,000 enrolled8 locationsNCT06699056
Recruiting
Not Applicable

Daily Hand-Held Vibration Therapy

CancerChemotherapeutic ToxicityNeuropathy+1 more
Indiana University16 enrolled3 locationsNCT04207437
Recruiting
Phase 2

A Study of Blood Pressure Control During Cancer Treatment

Breast CancerCardiotoxicity
Memorial Sloan Kettering Cancer Center130 enrolled7 locationsNCT06023576
Recruiting

Global Cardio Oncology Registry

Breast CancerCardiotoxicityCardiovascular Diseases+2 more
The Cleveland Clinic5,000 enrolled1 locationNCT05598879
Recruiting
Phase 2

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Ototoxicity, Drug-Induced
Kevin Winthrop105 enrolled7 locationsNCT05730283
Recruiting

TDM for Optimized Outcome in Patients With mRCC.

Renal Cell Carcinoma MetastaticKidney CancerDrug Toxicity+2 more
Niels Fristrup200 enrolled1 locationNCT04659343
Recruiting

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

Financial ToxicityBone Sarcomas
M.D. Anderson Cancer Center100 enrolled1 locationNCT07215611
Recruiting
Phase 2

Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

NephrotoxicityCisplatin Nephrotoxicity
Minia University50 enrolled1 locationNCT07564479
Recruiting

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

CancerQuality of LifeDistress, Emotional+4 more
Taipei Veterans General Hospital, Taiwan200 enrolled1 locationNCT06461780
Recruiting
Not Applicable

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

NeuropathyPeripheral NeuropathyPeripheral Neuropathy Due to Chemotherapy+1 more
Ka-Wai Ho60 enrolled2 locationsNCT07095998
Recruiting
Phase 2

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Anticholinergic Toxicity
Washington University School of Medicine42 enrolled1 locationNCT06399679
Recruiting

A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity

neurotoxicity
M.D. Anderson Cancer Center100 enrolled1 locationNCT06144151
Recruiting
Not Applicable

Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.

PainHead and Neck CancerQuality of Life+6 more
Mucosa Innovations, S.L.63 enrolled1 locationNCT05635929
Recruiting
Not Applicable

Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients

Breast CancerTreatment AdherenceDrug-Related Side Effects and Adverse Reactions+2 more
Azienda Sanitaria Locale di Asti124 enrolled1 locationNCT07524829
Recruiting
Not Applicable

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

CardiotoxicityAnthracycline-induced Cardiotoxicity
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)93 enrolled1 locationNCT07528586
Recruiting
Not Applicable

Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage

MalignancyGenotoxicityHyperbaric Oxygen
University Hospital, Angers60 enrolled1 locationNCT06999785
Recruiting
Phase 4

The STOP-MED CTRCD Trial

Heart FailureCancerCardiotoxicity+2 more
Dinesh Thavendiranathan335 enrolled14 locationsNCT06183437